This research used paid claims data to investigate the likelihood that patients achieved an adequate course of antidepressant drug therapy and the impact of completed therapy on health care costs. Completed therapy was defined as six or more months of uninterrupted therapy at an adequate dose as determined by AHCPR treatment guidelines. Apparent average daily dose for each prescription filled was calculated from data on the prescription paid claim and allowances were made for titration of dose to therapeutic levels and changes in antidepressant therapy. A total of 1648 new episodes of antidepressant therapy were identified for analysis. The likelihood of achieving an adequate course of antidepressant therapy was 22%. Completion rates varied significantly across antidepressants with fluoxetine achieving the highest completion rate at nearly 51%. Total health care costs were significantly lower for patients who completed therapy ( Ϫ $1487; P ϭ .0487) due primarily to lower ambulatory care costs ( Ϫ $1296; P ϭ .0110). Fluoxetine was the only antidepressant therapy which exhibited significantly lower total health care cost per patient relative to the older tricyclic antidepressants ( Ϫ $3524; P ϭ .0024). The total costs of treating depression in the ambulatory setting were found to vary widely across alternative antidepressants. Most of the cost-savings associated with fluoxetine use were associated with the increased likelihood of completed therapy. Further research is needed to verify if fluoxetine achieves better rates of completed therapy relative to other SSRI antidepressants using data from other settings.
Introduction
Major depressive disorder (MDD) is often undertreated in the ambulatory medical care setting, either because the disorder is not diagnosed by the clinician or the patient did not receive an adequate course of pharmacologic therapy. For example, Wells et al. [1] found that roughly half of 650 patients with a current depressive disorder were properly diagnosed by nonmental health specialists. Katon et al. [2] screened 767 patients with high primary care utilization profiles for possible depression. Over 44% of these patients were classified as possibly depressed, a rate far in excess of the 6-month prevalence rate of 1% to 3% estimated by Myers et al. [3] . Katon and his colleagues completed psychiatric interviews with 119 of these patients and found 24% to have a current episode of major depression and 68% to have had a lifetime history of major depression. Nearly half of the patients interviewed by the psychiatrist (47%) were evaluated as requiring drug therapy. However, only 45% of these patients had received antidepressant therapy in the previous 12 months (unrecognized depression), of whom 11% received an adequate course of therapy in terms of dose and duration (under-treated depression) [4] .
The failure of tricyclic antidepressants (TCAs) to adequately treat depressed patients in the outpatient setting is well established. For example, in the California Medicaid (Medi-Cal) program, nearly 80% of patients treated for depression failed to complete 6 months of uninterrupted drug therapy at minimum therapeutic dose [5] . In this study, interrupted or terminated therapy was found to increase total health care costs by over $1000 per patient in the first post-treatment year.
Fortunately, the newer serotonin re-uptake inhibitors (SSRIs) offer clinicians therapeutic alternatives to TCAs and heterocyclic antidepressants in the treatment of depression [6] [7] [8] [9] [10] [11] [12] [13] [14] . Several recent empirical studies suggest that SSRI antidepressants are better tolerated than conventional tricyclic and heterocyclic antidepressants by patients with major depressive disorders. These data, which were derived from real world clinical prac-tice settings, imply that SSRI patients experience lower health care costs. For example, Skaer et al. [15] found that the paroxetine reduced health care costs relative to TCAs in adult HMO patients with a single episode MDD who filled at least three antidepressant prescriptions and stayed with their initial medication. Previously, Sclar et al. [16] , had found similar results for fluoxetine in a study of comparable HMO patients. Building on these results, Sclar et al. [17] compared single-episode MDD patients prescribed sertraline, paroxetine and fluoxetine who used only the initial medication prescribed and filled a minimum of three prescriptions. In this study, fluoxetine was found to result in lower MDD-related treatment costs compared to sertraline and paroxetine. In a more recent study, Simon et al. [18] , in a comparison of fluoxetine to desipramine and imipramine, found that patients initiating therapy with a TCA were twice as likely to add a second antidepressant to their drug regimen or switch to an alternative drug compared to fluoxetine-treated patients.
This study used data from the Medi-Cal program to investigate the relative performance of SSRIs compared with the conventional tricyclic and heterocyclic antidepressants available to Medi-Cal recipients under the program's drug formulary. Three indicators of performance were investigated: the length of drug therapy achieved above minimum therapeutic dosing levels; the rate of augmentation or switching of antidepressant therapies; and health care costs by type of service for patients using antidepressants.
Data
The data for the analysis were derived from the Medi-Cal program, which finances a wide range of health care services for the poor and disabled, including outpatient prescription drugs. Medi-Cal generates a longitudinal research database for a random 5% sample of all recipients for as long as the sample recipient is eligible. This database provides patient-level demographic data combined with a summary of each claim for covered services paid on behalf of the recipient. Data include type of service, date of service, amount billed, amount paid, and units (days) of service. Prescription drug claims identify the specific product dispensed, quantity, strength and the date the prescription was filled. Prescription drugs are provided under Medi-Cal subject to a $1 copayment, though anecdotal information suggests that the copayment is not routinely collected by the pharmacy. Data for this analysis were drawn from the period January 1987 to July 1996.
Medi-Cal costs in the pre-and post-treatment periods were partitioned by type of service. The amounts paid by Medi-Cal understate total payments incurred by elderly and disabled Medi-Cal recipients who are dually eligible for Medicare which becomes the primary payer for these patients. The gaps between Medi-Cal payments and total payments for institutional care was bridged by multiplying days of hospital, and skilled nursing facility (SNF) and intermediate care facility (ICF) days by per diem cost estimates for these services. Hospital days were assigned a cost of $979 per day [19] , while SNF and ICF costs per day were valued at $270 [20] . To assure consistency, hospital and nursing home costs were estimated for all patients in the study, not just the Medicare eligible. In addition, the Medi-Cal cost for ambulatory services covered under Part B of Medicare were used to estimate total ambulatory care costs in both the pretreatment and post-treatment periods for all patients over 65 years of age. Actual Medi-Cal expenditures were used for patients under age 65. All reported noninstitutional expenditures were adjusted to 1994 dollars using historical Medi-Cal specific rates of fee schedule adjustments by type of service.
Providers do not routinely record diagnostic data on their claims for Medi-Cal payment. These omissions create two potential problems for the analysis. First, the selection of patients for study must be carefully crafted to focus the analysis on major depression. Solutions to this issue are discussed below. Second, missing diagnostic data preclude any attempt to limit the analyses to health care services consumed specifically for MDD. We do not believe that this latter limitation is relevant to a study of depression. Conducting this analysis using total post-treatment health care costs may provide a more accurate estimate of the impact of adequate dose and duration of therapy given the effects of depression on disability days, functional status, well-being, and the consumption of health services related to other illnesses. For example, Broadhead et al. [21] found that MDD increased the risk of disability by a factor of 4.78 and increased the number of disability days by 51%. Hays et al. [22] found patients with depressive symptoms to be comparable to or worse off in terms of functioning and well being than patients with eight major chronic medical conditions. Finally, Verbosky, Franco, and Zrull [23] found that depression increased the average length of hospital stays by 10 days even after controlling for primary diagnosis and severity of illness.
Methods

Inclusion and Exclusion Criteria
The study population was selected from patients initiating antidepressants between 1987 to mid-1996. A total of 12,724 new patient-episodes of antidepressant therapy were identified as potential study observations. Episodes of therapy were included in the analysis if:
• More than 6 months of pretreatment and 1
year of post-treatment data were available. • The patient did not use any antidepressant in the 6 month pretreatment period (new episode). • The patient was between 18 and 100 years of age. • The patient was not institutionalized in a nursing home within 30 days of the start of therapy.
New patient-episodes of antidepressant therapy were excluded from this sample for the following reasons:
• The patient's paid claims history included: (a) a paid claim with a recorded diagnosis of schizophrenia, mania, bipolar depression, dementia, chronic or transient organic psychotic conditions; (b) a prescription drug claim for a mood stabilizing medication or antipsychotic medication prior to the treatment episode; or (c) a prescription claim for a MAO inhibitor or for two different antidepressant medications as initial therapy (2333 episodes, 18.3%). • The patient's paid claims include a gap in all paid claims in excess of 3 months which may indicate a temporary loss of eligibility for patients under the age of 65 (2047 episodes, 16.1%). • The patient consumed more than $1000 in "other" services in the 6 months prior to the treatment episode, or more than $2000 in such services in the 1-year post-treatment period (1411 episodes, 11.1%). • No diagnosis of MDD (ICD-9296.2, 296.3) for patients taking TCAs or heterocyclic antidepressants (5257 episodes, 41.3%). • The patient consumed more than 120 days of acute hospital care or more than $100,000 in ambulatory care in the post-treatment period, or more than $50,000 in ambulatory care use in the 6-month period immediately prior to the initiation of antidepressant therapy (28 episodes, 0.2%).
The above criteria, designed to exclude patients with schizophrenia, bipolar disorder, and other severe forms of mental disorders based on either a recorded diagnosis or use of selected psychotropic medications, may not eliminate all of these patients from the analysis. For example, unpublished data from an ongoing analysis conducted by the authors into the cost of treating schizophrenia indicate that these patients may forego active therapy with antipsychotic medications for extended periods of time. It is also likely that these patients will have been treated with TCA antidepressants rather than the newer SSRI medications, leaving open the possibility that the TCA/MDD population is more likely to include patients with severe mental illnesses.
The significant loss of episodes due to a missing diagnosis of MDD is not surprising given the low rate of recording diagnosis on claims for payment by Medi-Cal providers. This exclusion criteria was necessary since tricyclic and heterocyclic antidepressants may be used to treat other nonmental disorders (e.g., sleep disorders, chronic pain). Since the therapeutic dose required to treat these medical conditions adequately is far below the minimum dose required for depression, including these non-MDD patients would bias downward the apparent treatment completion rates in the TCA and heterocyclic antidepressant populations. However, excluding TCA and heterocyclic patients without an MDD diagnosis could introduce bias into the analysis if the recording of the MDD diagnosis is correlated with the likelihood of treatment completion or future health care costs. While there is no evidence that this is the case, this limitation should be considered when evaluating the results of this analysis.
Fluoxetine, sertraline, and paroxetine were subject to prior authorization limiting their use to MDD. Therefore, for the primary analyses reported here, all patients treated with these medications were not required to have an MDD diagnosis recorded on their paid claims data. A sensitivity analysis was conducted in which only MDD patients were included. The drugs included for study and data on the final sample available for analysis are presented in Table 1 .
Definition of Adequate Dose and Duration of Therapy
The guidelines for the treatment of depression developed by the Agency for Health Care Policy and Research [24] were used as a basis for setting minimum therapeutic dose specifications for the analysis. The minimum dose requirements are listed in Table 1 . AHCPR guidelines specify that antidepressant drug therapy should continue for between 4 and 9 months. For this analysis, the duration of therapy required for "completed" treatment was set at 180 days (6 months).
Adequate dose and duration was established in this study using two methods. The first method was applied separately to the stream of prescription data available for the patient's initial antidepressant and to each added medication. This approach calculated the total milligrams of medication dispensed for each prescription (doses dispensed times strength) which was then divided by the calculated number of days between fill dates. The resulting estimate of average daily dose was then divided by the minimum therapeutic daily dose specified in Table 1 for the medication dispensed to derive the relative effective dose achieved for each prescription filled. In order to allow for dose titration, a patient was considered to have achieved a minimum therapeutic dose for the first initial prescription filled if the estimated effective dose exceeded 0.5, or 50%, of the drug's minimum therapeutic dose. The second prescription was deemed therapeutic if the estimated effective dose exceeded 0.75. Each subsequent prescription was deemed therapeutic if the calculated effective dose exceeded 0.9, thus allowing for limited early and late refills.
The number of therapeutic days achieved on the initial antidepressant dispensed was obtained by adding the number of days covered by each prescription until the effective dose dropped below target levels. If a second medication was used prior to 45 days from the last refill of the initial prescription, the therapeutic days achieved on subsequent medications were included in the total count of therapeutic days. The count of therapeutic days on the second medication followed the algorithm described above, again allowing for titration of the second medication. A similar procedure was applied to the second added medication. However, if a gap in excess of 45 days occurred between the last prescription filled of the preceding medication and an added antidepressant, the number of therapeutic days was limited to that achieved on the preceding drug or drugs. A separate count of therapeutic days achieved on added medications was also undertaken using the same criteria, regardless of any gap that may have transpired between medications, as a measure of treatment completion with secondary medications.
The method outlined above may not represent an accurate count of therapeutic days because of early refills, or augmentation and titration of the initial prescription with the same medication at a different strength. Therefore, a second method of calculating therapeutic days was developed which divides the total milligrams of medication dispensed (regardless of strength) by the total days covered by all prescriptions for a single medication, accounting for overlapping coverage and breaks in coverage in excess of 15 days. As before, this aggregate calculation of average daily dose was divided by the minimum daily therapeutic dose specified in the AHCPR guidelines to derive the relative effective dose achieved. If this value exceeded 0.9, then the entire period covered by the prescription(s) was identified as therapeutic. Similar calculations were undertaken for the first two added medications if the patient changed the medication used.
An adequate course of therapy (treatment completion) was defined as the patient having achieved 180 consecutive days of therapeutic dosing by either method of calculation, whether these days were achieved on the initial medication prescribed or on an added medication. A dichotomous variable indicating completion of therapy was used as an independent variable in regression models of post-treatment costs. A sensitivity analysis was conducted to determine if patients who complete therapy on a second antidepressant exhibit a different pattern of post-treatment costs relative to noncompleters than patients who complete therapy without a change in medications. A determination was made whether the patient completed an adequate course of therapy on their initial or secondary medication and these dichotomous variables were used in regression models of post-treatment cost. Descriptive Statistics Table 2 displays the population characteristics by type of initial therapy used. In general, all five treatment groups appear quite similar with a few notable exceptions. SSRI patients tend to be less urban and to have higher drug expenditures in the prior period than either TCA or heterocyclic patients. Even with the higher drug expenditures, SSRI patients were more likely to fill all of their prescriptions at a single pharmacy. SSRI patients were also more likely to have experienced a prior episode of antidepressant therapy than the other treatment groups. However, fluoxetine, TCA, and heterocyclic patients were more likely to have used the services of a psychiatrist than sertraline or paroxetine patients. Finally, sertraline, paroxetine, and heterocyclic patients had higher levels of total costs in the prior six months ($3678-$4678) than TCA patients ($3299) or fluoxetine patients ($3011). Some of these differences are related to the higher rates of hospitalizations for heterocyclic and sertraline patients in the period prior to treatment.
Statistical Methods
Multivariate ordinary least-squares (OLS) regression analyses were used to investigate the impact of the patient having achieved adequate dose and duration of antidepressant drug therapy on health care costs. In order to control for baseline differences across alternative antidepressants, all models used independent variables based on data recorded on the paid claims. Demographic data included age, gender, urban or rural residence, and year in which treatment was initiated (time trend). The prior use of health care, including the use of psychiatrists, psychologists and mental health centers, was measured as the total payments for these services during the pretreatment period aggregated by provider type. Dichotomous diagnostic mix variables were created based on the ICD-9 codes recorded on services consumed in the pretreatment period. The patient's use of medications for anxiety, prescribed narcotics, and hypnotics in the pretreatment period were measured by dichotomous variables based on paid claims for drugs in these therapeutic classes. Similar drug profile variables were created indicating the use of medications for heart disease, hypertension, hormone replacement therapy, arrhythmia, and Parkinson's disease, based on the patient's prescription claims in the pre-and post-treatment periods.
A dichotomous variable was created indicating whether the patient used a single pharmacy for all prescriptions filled during the pre-and post-treatment periods. Because a new episode was defined after each break in therapy in excess of 6 months, each patient could have multiple new episodes of antidepressant therapy. A variable was created that counted the number of antidepressant treatment episodes that preceded each episode in the study. While this variable is not an accurate measure of the true number of prior episodes due to the truncation of the data prior to January 1987, it does provide some measure of recurrent depression.
Any reduction in post-treatment health care costs associated with adequate dose and duration antidepressant drug therapy will likely be offset by increased drug costs, thus making the impact of completed therapy on total costs ambiguous. In order to clarify the effects of an adequate course of therapy on post-treatment health care costs, the analysis focused on the components of health care costs, including total costs net of drug costs. The log of costs was used as a dependent variable in addition to actual costs to control for non-normality. Sensitivity analyses were conducted in which the impact of achieving adequate dose and duration on an initial course were compared to completion on a secondary course of antidepressant therapy. Both effects were measured relative to noncompleters. In these sensitivity analyses, it was hypothesized that the need to add a second antidepressant medication would be associated with increased costs or reduced savings.
An intent-to-treat analysis was conducted to compare outcomes across alternative medications when used as initial therapy. Logistic regression techniques were used to estimate the impact of the initial medication selection on the probability that a patient achieved adequate dose and duration of therapy. Cost models were then estimated using both actual costs and log costs. Patients who used a tricyclic antidepressant as their initial therapy were defined as the index population for the intent-to-treat analyses.
Results
Cost Impacts of Adequate Dose and Duration
Only 358 of 1648 MDD-patients (21.7%) with a new episode of antidepressant therapy achieved 6 months of uninterrupted therapeutic dosing. Data describing these two populations are provided in Table 3 . Patients who achieved adequate dose and duration were more likely to have used an antipsychotic medication or to have added a second or third drug while continuing their initial therapy (augmenters), though they may have dropped their initial therapy at a later date. Patients who did not achieve adequate dose or duration were more likely to have added these medications while terminating their initial therapy (switchers).
Post-treatment costs for patients with adequate dose and duration of therapy were lower for all components of costs except drug costs and the costs of other services, including dental services. These data, which were not adjusted for differences in the prior use of health care or other factors, indicate that adequate dose and duration of antidepressant therapy reduces total costs by nearly $1900 in the first post-treatment year, primarily due to lower ambulatory care costs ($1830). Table 4 summarizes the estimated impact on actual costs and log-costs of adequate dose and duration of antidepressant therapy. The first column lists results for the analyses in which all completers are considered as a single group. The last two columns list results for the analyses in which patients who achieved adequate dose and duration on their initial medication or on a subsequent therapy are compared separately to noncompleters.
The results for all completers combined display a pattern of decreased ambulatory care costs ( Ϫ $1296, P ϭ .0110), nursing home costs ( Ϫ $348, P ϭ .2748) and hospital costs ( Ϫ $230, P ϭ .4190) offset by higher drug costs ( ϩ $323, P ϭ .0282). Adequate dose and duration of therapy was associated with a significant reduction in total costs ( Ϫ $1487, P ϭ .0479). The results in the models using the log-cost were consistent with the above results, although the estimated effects of adequate dose and duration of therapy on net and total costs were not statistically significant.
As expected, the savings associated with an adequate course of therapy were more pronounced when completion on an initial course of therapy was compared separately to noncompleters from completion on secondary courses of therapy. The reductions associated with achieving adequate therapy without a break in therapy were negative and significant for ambulatory care costs ( Ϫ $1499, P ϭ .0080), net cost ( Ϫ $2320, P ϭ .0033) and total costs ( Ϫ $2080, P ϭ .0125).
Patients who achieved adequate dose and duration on a secondary course of antidepressant therapy displayed smaller estimated savings in ambulatory care compared to noncompleters, whose savings were offset by much higher drug costs than patients who completed their initial course of therapy ($608 versus $239). As a result, patients who achieved an adequate dose and duration on a secondary course of therapy displayed costs roughly equivalent to noncompleters, though none of these estimates were statistically significant with the exception of higher drug costs. The results from the analyses that used log-costs as a dependent variable were generally consistent with these results.
Several other results can be derived from the regression models of total costs. Patients who patronized one pharmacy for all of their prescriptions were estimated to use $2951 less in total health care in the post-treatment year than patients who used two or more pharmacies ( P Ͻ .0010). This "one-pharmacy" effect is consistent with previous results using Medi-Cal data that found single pharmacy cost reductions of $1242 per year for antihypertensive patients [25] ; $1822 per year for patients treated for onychomycosis [26] ; and $550 to $580 over 3 months for cimetidine patients using concomitant medications with significant adverse drug reaction potential [27] .
Prior use rates for health care services are highly predictive of future costs. For example, each dollar spent on prescription drugs in the prior 6 months is correlated with a $6.99 increase in costs in the following year ( P Ͻ .0001). Corre-sponding results for hospital and ambulatory care spending in the prior period are much smaller, but statistically significant ($0.14, P ϭ .0175 and $0.38, P Ͻ .0001, respectively).
An Intent-to-Treat Analysis of Alternative Initial Therapies
An intent-to-treat analysis was conducted which compared outcomes based on the medication used as initial therapy. Five alternative initial antidepressant therapies were compared: TCAs, heterocyclics, paroxetine, sertraline, and fluoxetine. These data must be interpreted with caution given the relatively small number of patients treated with each of the three SSRI antidepressants and the relatively short time for which paroxetine and sertraline were available to Medi-Cal patients.
The drug profile data in Table 5 indicate important differences across alternative therapies. First, termination rates after two prescriptions vary widely, ranging from nearly 71.2% for paroxetine to 28.6% for fluoxetine, which also had the largest proportion of patients purchasing six or more prescriptions (42.1%). The same pattern appears for early terminations even after accounting for changes in the medication used.
Early terminations of initial therapy were a major factor in determining if the patient achieves an adequate course of antidepressant therapy; the other factor was under-dosing. Not surprisingly, approximately 13% to 14.5% of patients initiating therapy with a tricyclic or heterocyclic antidepressant achieved an adequate course of therapy on their initial medication, with an additional 4% to 5% of patients completing therapy on a secondary drug. The completion rates for sertraline and paroxetine patients were similar to the older antidepressants (18.7% and 9.3%, respectively), and 5% to 6% of completions were achieved on an added antidepressant. In comparison, 55% of patients treated with fluoxetine achieved an adequate dose and duration of antidepressant therapy, either on fluoxetine (50.7%) or on a second antidepressant (4.3%).
A multivariate logistic analysis of the likelihood of completing an adequate course of therapy was estimated to measure the relative impact of the initial medication prescribed using TCA patients as the comparison group. The results of the logistic analysis are summarized as odds ratios with respect to TCAs and are listed in Table 5 . The odds ratio results indicate that fluoxetine patients were roughly 5.8 times more likely to achieve adequate dose and duration of therapy relative to TCA medications, taking into account demographic, diagnostic, and prior use characteristics of the patient (P Ͻ .0001). Sertraline patients were 62% more likely to achieve adequate dose and duration than TCA patients (odds ratio ϭ 1.622, P ϭ .0447). Patients prescribed paroxetine or heterocyclics as initial therapy were not statistically different than TCA patients.
The observed differences in the likelihood of achieving adequate dose and duration across alternative SSRIs are unexpected given the extensive clinical trial data for these products which show little difference in efficacy or side-effect profiles. However, the observed differences in initial therapy completion rates favoring fluoxetine, and to a lesser extent sertraline, are supported by other data in Table 5 . When only those patients using a psychiatrist before or soon after the date of the initial antidepressant prescription were considered, completion rates for TCAs and heterocyclics as the initial medication improved to 18% and 26%, respectively, while the paroxetine completion rate did not improve. However, these rates still lagged the corresponding rate for fluoxetine (56%) and sertraline, which improved significantly to 53%. The rates of augmentation, switching, and antipsychotic drug use were also consistent with the differential in adequate dose and duration rates across initial therapies. Patients who were prescribed fluoxetine as initial therapy switched to a second antidepressant in 10% of treatment episodes. Switch rates for all other antidepressants ranged between 24.4% (heterocyclics) and 30.1% (TCAs). The fluoxetine augmentation rate (5.7%) was lower than that found for TCA and heterocyclic patients (8-10%), and higher than that found for paroxetine (3.1%) and sertraline (5.4%). The SSRIs had similar rates of augmentation with an antipsychotic medication within 60 days of the initiation of therapy. Finally, in our sample, fluoxetine was found to be more likely to achieve adequate dose and duration when used as a secondary medication (35.3%) compared to all other alternative antidepressants (0-20%). One possible explanation for the differences in the likelihood of achieving an adequate course of therapy across the SSRIs is the length of time each product was available for physicians to become familiar with their use. This hypothesis is supported by the completion rate data derived for those episodes of drug therapy initiated after July 1, 1994 (the last year for which complete data were available). The completion rates for patients treated during this period were 38.7% for paroxetine (N ϭ 26), 33.3% for sertraline (N ϭ 54), and 47.5% for fluoxetine (N ϭ 40). Fluoxetine performed much better, however, when 70-80 of the earliest episodes of care are compared for each product. The rate of adequate dose and duration for these episodes are 59.5% for fluoxetine (N ϭ 74), 16 .2% for sertraline (N ϭ 68), and 6.9% for paroxetine (N ϭ 72).
The differences between fluoxetine and TCAs as initial therapy observed here are supported by other studies. The cumulative rate at which TCA and fluoxetine patients switched or augmented their initial therapy with a second antidepressant (38.4% and 18.0%, respectively) are very similar to rates reported by Simon et al. [18] . In a prospective comparison of TCAs to fluoxetine conducted at Group Health Cooperative of Puget Sound, 48% of desipramine patients, 43% of imipramine patients, and 20% fluoxetine patients were found to have switched therapies within 6 months.
Multivariate analyses of cost effects associated with the type of initial therapy prescribed are reported in Table 6 . Patients prescribed a TCA as initial therapy again served as the comparison group in these analyses. Fluoxetine and sertraline were the only alternatives to TCAs for which statistically significant cost-savings were demonstrated. In the analysis of actual costs, fluoxetine as initial therapy was associated with significant reductions in ambulatory care costs (Ϫ$2125, P ϭ .0070), net costs (Ϫ$3572, P ϭ .0012), and total costs (Ϫ$3524, P ϭ .0024) during the first post-treatment year relative to TCAs. These results were confirmed in the log-cost analyses with the exception of total costs (Ϫ13.1%, P ϭ .1275). Sertraline was found to reduce nursing home costs (Ϫ$1026, P ϭ .0487), other costs (Ϫ$230, P ϭ .0215) and the log of net costs (Ϫ29%, P ϭ .0149) and other costs (Ϫ111%, P ϭ .0006). Paroxetine as an alternative to TCAs as initial therapy displayed lower total costs in the analyses using actual costs, though none of these estimated effects were statistically significant. Heterocyclics were estimated to increase drug costs relative to TCAs in both the actual cost and log-cost analyses.
Sensitivity Analyses
Four sensitivity analyses were performed. First, Thompson et al. [28] found that 19.1% of 1200 SSRI patients terminated therapy early and were low-cost patients relative to patients who switched or augmented their therapy. An analysis was conducted using the augmented sample in which patients who terminated antidepressant therapy after only one to two prescriptions for their initial med- A second sensitivity analysis was conducted in which the 28 patients with very high use of ambulatory or hospital services were included in the analysis. Including these patients had two effects in the analyses of the cost effects of completed therapy. First, the savings associated with completed therapy increased from Ϫ$1487 (P ϭ .0479) to Ϫ$2664 (P ϭ .0881). However, the variance in the data increased significantly, thus reducing the statistical significance of some parameter estimates. In the intent-to-treat analyses, the savings associated with all alternatives to the TCAs increased with the exception of fluoxetine, which was reduced from Ϫ$3524 (P ϭ .0024) to Ϫ$1928 (P ϭ .4208). None of the alternatives were found to be statistically different from the TCAs in terms of total costs and fluoxetine was found to have the largest savings.
The use of antipsychotic medications in the post-treatment period was higher in the TCA and heterocyclic patient populations (Table 5 ), suggesting that patients with psychotic depression were treated predominately with these products. Since concomitant psychoses are likely to significantly increase costs, a sensitivity analysis was conducted in which antipsychotic drug use in the post-treatment period was included into the models of post-treatment cost. While antipsychotic drug use in the post-treatment period is correlated with significantly higher hospital and nursing home costs in the post-treatment period, inclusion of this dichotomous variable in the cost models did not change the estimated impact of completion of therapy or the intent-to-treat analyses.
Finally, SSRI patients included in the primary models reported above were not screened for whether an MDD diagnosis had been recorded on their paid claim file. A sensitivity analysis was conducted in which all cost and completion models were re-estimated with only confirmed MDD patients included in the analyses. The results from these models, including the intent-to-treat analyses, parallel closely the results reported above, although the level of statistical significance has been reduced due to the reduction in available observations.
Discussion
Only 22% of Medi-Cal MDD patients studied here achieved an adequate course of therapy in terms of dose and duration. This disappointing completion rate is not unexpected. Katon et al. [29] found that 50% of HMO members achieved adequate dose and duration for 90 days or more. The lower completion rates in the Medi-Cal population are likely due to the longer period of time used to define completed therapy and the characteristics of a Medicaid population. For example, educational attainment and patient knowledge concerning the disease state and prescribed therapy have long been known to be positively correlated with patient compliance with drug therapy [30] . Antidepressant drug therapy completion rates may be higher in non-Medicaid populations.
This analysis found a correlation between an adequate course of antidepressant therapy and lower ambulatory health care costs, which were offset by higher drug costs. The effect of completed therapy on overall health care costs appears to indicate savings, though these results were not always statistically significant. Additional study is required with a larger sample of patients to verify the cost savings associated with adequate dose and duration as measured in this study.
The data for the three SSRI antidepressants studied are less compelling due to the limited sample size available for analysis and the relatively short time period in which paroxetine and sertraline were available to physicians. In the limited sample of SSRI patients, however, fluoxetine demonstrated significantly higher rates of adequate dose and duration as initial therapy than all other alternatives studied. These results were confirmed in a multivariate logistic regression analysis in which fluoxetine was estimated to increase the likelihood of achieving an adequate course of therapy relative to TCAs by a factor of 5.8. The use of multivariate estimation procedures permitted factors such as baseline differences in cohort age or severity to be controlled statistically. While confirmation of the differences between the SSRIs is necessary due to the limited sample available for this analysis, the data required for such confirmation are readily available to most managed care plans and HMOs. At a minimum, simple counts of the number of prescriptions filled and medica-tion switch rates can be easily observed from pharmacy data.
Similarly, the results indicating that fluoxetine used as initial therapy reduced the total cost of treating MDD patients when compared to TCAs can be questioned due to small sample size and possible unobserved differences between these patient groups. Two factors tend to temper these concerns. First, the estimated cost effects associated with fluoxetine are consistent with expectations given fluoxetine's higher rate of adequate dose and duration of therapy and the estimated effects of completed therapy on costs. Specifically, fluoxetine patients experienced lower ambulatory care costs that were partially offset by increased drug costs. Second, the models used to estimate the cost effects of alternative therapies to TCAs controlled for prior use, patient demographics, and baseline drug profiles and diagnostic data. Finally, the other SSRIs were also associated with lower costs relative to TCAs though the estimated cost-savings were not statistically significant.
Finally, analyses based on paid claims data have significant limitations that may affect the internal validity of these results. First, the limited reliability of diagnostic data recorded on paid claims makes it difficult to limit the analysis to MDD patients only, or to fully account for possible differences in severity and comorbidities across patients. Biased estimates of differences across antidepressants will result if drug selection is correlated with severity of illness or health status. While the statistical models specified in this analysis include multiple independent variables designed to account for these differences, the extent of possible residual bias is unknown. Second, patients who lost their Medi-Cal eligibility during the post-treatment period were dropped from the analysis due to missing data concerns. Given the debilitating effects of depression [21] , it is likely that patients who completed drug therapy exhibited a higher likelihood of exclusion due to missing data. If this is the case, the observed rate of completed therapy (22%) is biased downward, as are the estimates of potential cost savings due to completed therapy.
